Clinical trial
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
NCT00354978 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00354978 |
|---|---|
| Title | Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients |
| Official title | Phase II Study of Irinotecan, Leucovorin, 5-Fluorouracil (FOLFIRI) Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry Pfizer |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | 5-Fluorouracil, Bevacizumab, Leucovorin, Irinotecan |
| Enrollment | 49 |
| Start date | Jan 1, 2005 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Jul 20, 2006 |
| Last update posted | Oct 21, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: